Announcements Trials
Browse Landscape

Phase

Phase 2 188Phase 3 92Phase 1 69Phase 1/2 56Phase 4 9Phase 2/3 5Phase NA 4Phase EARLY_PHASE1 4

Status

Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Renal Insufficiency 1Primary Myelofibrosis 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Breast Neoplasms 1

Interventions

Cyclophosphamide 6Dexamethasone 5fludarabine 4Bortezomib 468Ga-pentixafor 4Melphalan 3Lenalidomide 3Granulocyte Colony-Stimulating Factor 3Positron Emission Tomography Computed Tomography 2Fluorodeoxyglucose F18 2Filgrastim 2tocilizumab 1ruxolitinib 1pomalidomide 1methyl prednisolonate 1ioversol 1iberdomide 1fludarabine phosphate 1eltrombopag 1elotuzumab 1daratumumab 1carfilzomib 1blinatumomab 1Thalidomide 1Tacrolimus 1Simvastatin 1Prochlorperazine 1Pemetrexed 1Ondansetron 1Mycophenolic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Multiple Myeloma × Bortezomib × Clear all
NCT06142396 2026-03-12

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Augusta University

Phase EARLY_PHASE1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT01594242 2019-04-16

Autophagy Induction After Bortezomib for Myeloma

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Completed
11 enrolled
Plasma cell

Multiple Myeloma

NCT02109861 2015-12-08

Phase-0-MM

Aalborg University Hospital

Phase EARLY_PHASE1 Unknown
6 enrolled
Plasma cell

Multiple Myeloma

NCT01537861 2015-01-26

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Washington University School of Medicine

Phase EARLY_PHASE1 Terminated
7 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡